-
Allosteric PDK4 Inhibitors: Evidence from Compound 8c
2026-10-05
The 2019 Journal of Medicinal Chemistry study identified a new anthraquinone-derived series of allosteric pyruvate dehydrogenase kinase 4 inhibitors, with compound 8c showing an in vitro IC₅₀ of 84 nM. Its metabolic, pharmacokinetic, mouse-model, and cell-based findings support further preclinical investigation, while remaining insufficient to establish clinical efficacy or disease-specific therapeutic benefit.
-
WAY-100635: 5-HT1A Antagonist Research Guide
2026-10-04
WAY-100635 is a selective 5-HT1A receptor antagonist used in serotonin receptor antagonist research, binding studies, functional pharmacology, and translational neuroscience. Available evidence supports receptor-level interpretation, but the 2026 cannabidiol pain study does not establish a direct 5-HT1A mechanism.
-
5-Methoxy-UTP: Evidence, Mechanism, and Limits
2026-10-03
5-Methoxy-UTP is listed as product B8061, but the supplied dossier does not establish its enzymatic incorporation, RNA effects, or formulation performance. The cited LNP study supports composition-aware modeling through COMET, while its findings do not directly validate this nucleotide analogue.
-
Phenothiazines Boost Macrophage Antibacterial Activity
2026-10-02
A 2025 Frontiers in Immunology study shows that phenothiazines strengthen macrophage antibacterial activity through coordinated lysosomal activation, autophagy, and reactive oxygen species accumulation. The work supports host-directed therapy as a strategy for intracellular bacterial infections while highlighting the need for compound-specific validation and careful pathway controls.
-
Ionomycin Free Acid for FAK–TNBC Calcium Studies
2026-10-01
Ionomycin free acid provides an acute, controllable calcium ionophore perturbation for testing whether intracellular calcium influences FAISL–FAK signaling, adhesion, and TNBC phenotypes. This workflow complements genetic experiments by pairing calcium measurements with FAK stability and Calpain 2-linked proteolysis readouts.
-
Cepharanthine Workflows for Organoid Research
2026-10-01
Build a translational Cepharanthine workflow that progresses from controlled stromal-cell assays to patient-derived endometrial organoids and lesion models. The approach separates formulation, viability, cell-cycle arrest, DNA damage, and apoptosis signals so a biscoclaurine alkaloid can be evaluated without overstating preclinical evidence.
-
Gap26 for 3D Osteocyte Calcium Signaling
2026-09-30
Gap26 adds a controlled connexin 43 perturbation step to 3D osteocyte microfluidic assays, helping distinguish mechanosensing from signal propagation. This workflow translates pulsatile-flow biology into measurable calcium-wave and ATP-release endpoints while preserving practical controls for peptide dosing, imaging, and interpretation.
-
Linoleic Acid (C18:2) Workflow Guide
2026-09-30
Linoleic Acid (C18:2(9Z,12Z)) provides a defined lipid input for oxidative stress, membrane, erythrocyte, epithelial migration, and essential fatty acid deficiency workflows. It is suitable for controlled in vitro and animal research, but its water insolubility, oxidation sensitivity, and lack of assay-specific dosing evidence require fresh preparation, vehicle controls, and pilot optimization.
-
MFGE8–ANXA1/SMAD2/3 Targeting in Pancreatic Fibrosis
2026-09-29
This study links umbilical cord-derived mesenchymal stem cell extracellular vesicles to suppression of pancreatic fibrosis through an MFGE8-dependent ANXA1–SMAD2/3 axis. Its development of rhMFGE8 nanoparticles extends the work from cell-based repair toward a potentially more controllable, cell-free antifibrotic strategy.
-
Recombinant Annexin V Maps Cardiomyocyte Death After I/R
2026-09-29
This Circulation study established labeled human recombinant Annexin V as an in vivo probe for phosphatidylserine externalization during myocardial ischemia and reperfusion. By resolving cell death earlier than DNA-fragmentation methods alone and responding to pharmacological intervention, the approach helped define when cardiomyocytes become vulnerable after reperfusion.
-
UHRF1–TGM2 Axis in Senile Osteoporosis
2026-09-28
This study links reduced UHRF1-associated DNA 5-methylcytosine, super-enhancer redistribution, and impaired mesenchymal stem-cell osteogenesis to altered TGM2-regulated autophagic flux. Its multi-omics and mouse-model findings identify an epigenetic pathway that merits further testing as a contributor to age-related bone loss, while leaving important questions about causality and human translation open.
-
CCG-1423: Mapping RhoA Signal Branches
2026-09-27
CCG-1423 is a RhoA inhibitor research tool for distinguishing MRTF-A-dependent transcription from RhoA/ROCK-driven cytoskeletal effects. This guide uses recent MVC findings to show how pathway placement, controls, and assay choice shape interpretable results.
-
Ziprasidone Targets GOT1 in Pancreatic Cancer
2026-09-26
A 2022 study identified ziprasidone as a non-competitive inhibitor of GOT1 and linked its activity to disrupted glutamine metabolism, altered redox balance, and reduced pancreatic ductal adenocarcinoma cell growth. The authors combined biochemical and cellular assays with GOT1 knockdown and a SW1990 xenograft model, providing preclinical evidence for a metabolic mechanism rather than evidence of clinical cancer efficacy.
-
WP1066 and the Context of JAK2/STAT3 Biology
2026-09-26
WP1066 offers a cell-permeable way to interrogate JAK2/STAT3 signaling in cancer models. New macrophage-focused bone-repair findings also underscore a translational imperative: pathway direction and cell context matter as much as target selection.
-
CTP Solution for p21 mRNA Workflow Design
2026-09-25
See how CTP Solution can support the in vitro transcription step behind mRNA research, including workflows inspired by localized p21 mRNA delivery for bladder cancer. The article separates practical starting conditions from study findings and shows how to troubleshoot nucleotide balance, RNA integrity, and downstream readouts.